Comparing Drug Shortages Experienced by Institutions With National Metrics
This article describes the reasons for conflicting information from different sources.PMID:38366856 | DOI:10.1093/oncolo/oyad350 (Source: The Oncologist)
Source: The Oncologist - February 17, 2024 Category: Cancer & Oncology Authors: Austin Pytlowany Noah Leja Stanley Kent Source Type: research
Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review
Oncologist. 2024 Feb 16:oyae007. doi: 10.1093/oncolo/oyae007. Online ahead of print.ABSTRACTWe performed a systematic literature review to identify and summarize data from studies reporting clinical efficacy and safety outcomes for trifluridine/tipiracil (FTD/TPI) combined with other antineoplastic agents in advanced cancers, including metastatic colorectal cancer (mCRC). We conducted a systematic search on May 29, 2021, for studies reporting one or more efficacy or safety outcome with FTD/TPI-containing combinations. Our search yielded 1378 publications, with 38 records meeting selection criteria: 35 studies of FTD/TPI-co...
Source: The Oncologist - February 17, 2024 Category: Cancer & Oncology Authors: Kohei Shitara Alfred Falcone Marwan G Fakih Ben George Raghav Sundar Sandip Ranjan Eric Van Cutsem Source Type: research
Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study
CONCLUSION: Toripalimab plus apatinib treatment in second-line therapy of advanced GC/EGJC showed manageable toxicity but did not improve clinical outcomes relative to PC treatment (ClinicalTrials.gov Identifier: NCT04190745).PMID:38366886 | DOI:10.1093/oncolo/oyae005 (Source: The Oncologist)
Source: The Oncologist - February 17, 2024 Category: Cancer & Oncology Authors: Qing Wei Xiaoqing Xu Jingjing Li Chang Wang Weijun Chen Yanru Xie Cong Luo Lei Chen Jiadong Chu Wei Wu Zhe Han Yanlian Yang Zhiyuan Hu Qi Xu Jieer Ying Source Type: research
Association between Homologous Recombination Repair Defect Status and Long-Term Prognosis of Early HER2-Low Breast Cancer: A Retrospective Cohort Study
CONCLUSION: Higher HRD scores were associated with poorer PFI outcomes, particularly in people with HR+/HER2-low. Varied HRD states exhibited distinctions in HRRGs and the tumor immune landscape. These insights have the potential to assist clinicians in promptly identifying high-risk groups and tailoring personalized treatments for patients with HER2-low EBC, aiming to enhance long-term outcomes.PMID:38366907 | DOI:10.1093/oncolo/oyae021 (Source: The Oncologist)
Source: The Oncologist - February 17, 2024 Category: Cancer & Oncology Authors: Jiayi Chen Yingying Zhu Wei Wu Yaqi Xu Wenqian Yang Li Ling Qun Lin Shijie Jia Yuan Xia Zihao Liu Yaping Yang Chang Gong Source Type: research
Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials
CONCLUSIONS: These analyses suggest PD-L1 expression has an appreciable impact on clinical outcomes for patients with NSCLC treated with ICI. As the impact of PD-L1 expression on outcomes may vary across regions, it is critical that future trials are multiregional and enroll a diverse patient population.PMID:38349736 | DOI:10.1093/oncolo/oyae006 (Source: The Oncologist)
Source: The Oncologist - February 13, 2024 Category: Cancer & Oncology Authors: Jonathon Vallejo Harpreet Singh Erin Larkins Nicole Drezner Biagio Ricciuti Pallavi Mishra-Kalyani Shenghui Tang Julia A Beaver Mark M Awad Source Type: research
Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials
CONCLUSIONS: These analyses suggest PD-L1 expression has an appreciable impact on clinical outcomes for patients with NSCLC treated with ICI. As the impact of PD-L1 expression on outcomes may vary across regions, it is critical that future trials are multiregional and enroll a diverse patient population.PMID:38349736 | DOI:10.1093/oncolo/oyae006 (Source: The Oncologist)
Source: The Oncologist - February 13, 2024 Category: Cancer & Oncology Authors: Jonathon Vallejo Harpreet Singh Erin Larkins Nicole Drezner Biagio Ricciuti Pallavi Mishra-Kalyani Shenghui Tang Julia A Beaver Mark M Awad Source Type: research
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-M ünster Protocol With Rituximab and Consolidative Autologous Transplantation
CONCLUSION: Intensive treatment according to BFM protocol, with rituximab and ASCT, appears feasible, safe, and highly effective in adult patients with BL, as confirmed by long-term survival rates reflecting response maintenance.PMID:38339976 | DOI:10.1093/oncolo/oyae017 (Source: The Oncologist)
Source: The Oncologist - February 10, 2024 Category: Cancer & Oncology Authors: Alessandro Broccoli Lisa Argnani Gabriele Gugliotta Cinzia Pellegrini Beatrice Casadei Gianmarco Bagnato Marianna Gentilini Vittorio Stefoni Pier Luigi Zinzani Source Type: research
Consuming Patients' Days: Time Spent on Ambulatory Appointments by People With Cancer
CONCLUSION: Patients often spent several hours pursuing ambulatory cancer care on a given day. Accounting for opportunity time costs and the coordination of activities around ambulatory care, these results highlight the substantial time burdens of cancer care, and support the notion that many days with ambulatory health care contact may represent "lost days."PMID:38339991 | DOI:10.1093/oncolo/oyae016 (Source: The Oncologist)
Source: The Oncologist - February 10, 2024 Category: Cancer & Oncology Authors: Sana Kagalwalla Alexander K Tsai Manju George Anna Waldock Sydney Davis Patricia Jewett Rachel I Vogel Ishani Ganguli Christopher Booth Stacie B Dusetzina Gabrielle B Rocque Anne H Blaes Arjun Gupta Source Type: research
Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer
CONCLUSION: The effectiveness of cyclin-dependent kinase 4/6 inhibitors is unlikely to be affected by concomitant PPI use. Future prospective pharmacokinetic studies are warranted.PMID:38340010 | DOI:10.1093/oncolo/oyae015 (Source: The Oncologist)
Source: The Oncologist - February 10, 2024 Category: Cancer & Oncology Authors: Kaori Takahashi Ryuji Uozumi Toru Mukohara Tetsu Hayashida Midori Iwabe Hirotoshi Iihara Kanako Kusuhara-Mamishin Yuko Kitagawa Masami Tsuchiya Mika Kitahora Aiko Nagayama Shinkichi Kosaka Yoshimi Asano-Niwa Tomoko Seki Koji Ohnuki Akio Suzuki Fumiko Ono Source Type: research
Quantifying Chemotherapy Delivery in Older and Younger Women With Early-Stage Breast Cancer Using Longitudinal Cumulative Dose
CONCLUSION: Within our cohort, adjuvant TC was well tolerated with LCD curves showing largely on-time and full-dose administration. Subgroup analyses showed only slight decreases in adjuvant TC LCD for patients aged 65+ versus <65 years.PMID:38330406 | DOI:10.1093/oncolo/oyad349 (Source: The Oncologist)
Source: The Oncologist - February 8, 2024 Category: Cancer & Oncology Authors: Joyce Pak Kirsten A Nyrop Hyman B Muss Moriah K Forster Jennifer L Lund Source Type: research
Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical Trials
CONCLUSION: The irAExplorer is a user-friendly resource that offers exploration, validation, and discovery of treatment- or cancer-specific irAEs across pan-cancer cohorts. We envision that irAExplorer can serve as a valuable resource to cross-validate users' internal datasets to increase the robustness of their findings.PMID:38330451 | DOI:10.1093/oncolo/oyae012 (Source: The Oncologist)
Source: The Oncologist - February 8, 2024 Category: Cancer & Oncology Authors: Muhammad Zaki Hidayatullah Fadlullah Ching-Nung Lin Samuel Coleman Arabella Young Abdul Rafeh Naqash Siwen Hu-Lieskovan Aik Choon Tan Source Type: research
Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers
CONCLUSION: In GI cancers, MTAP-loss occurs as part of 9p21 loss and has an overall prevalence of 8%. MTAP-loss occurs in 22% of PDAC, 15% of IHCC, 8.7% of gastroesophageal adenocarcinoma, 2.4% of hepatocellular carcinoma, and 1.1% of CRC and is not mutually exclusive with other targetable mutations.PMID:38330461 | DOI:10.1093/oncolo/oyae011 (Source: The Oncologist)
Source: The Oncologist - February 8, 2024 Category: Cancer & Oncology Authors: Natalie Y L Ngoi Tin-Yun Tang Catia F Gaspar Dean C Pavlick Gregory M Buchold Emma L Scholefield Vamsi Parimi Richard S P Huang Tyler Janovitz Natalie Danziger Mia A Levy Shubham Pant Anaemy Danner De Armas David Kumpula Jeffrey S Ross Milind Javle Jordi Source Type: research
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma
CONCLUSION: In patients with localized, poor prognosis HCC, pembrolizumab in addition to glass Y90 radioembolization demonstrated promising efficacy and safety consistent with prior observations (ClinicalTrials.gov Identifier: NCT03099564; IRB Approved: 16-3255 approved July 12, 2016).PMID:38325328 | DOI:10.1093/oncolo/oyad331 (Source: The Oncologist)
Source: The Oncologist - February 7, 2024 Category: Cancer & Oncology Authors: Shawn Yu Menggang Yu Barry Keane David M Mauro Paul R Helft William P Harris Hanna K Sanoff Matthew S Johnson Bert O'Neil Autumn Jackson McRee Ashwin Somasundaram Source Type: research
The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review
In conclusion, while ICI monotherapy has limited efficacy in MSS CRC, combination strategies hold promise to enhance survival outcomes. Further research is necessary to identify optimal combination approaches, predictive biomarkers for treatment response, as well as enrollment according to tumor molecular characteristics.PMID:38309719 | DOI:10.1093/oncolo/oyae013 (Source: The Oncologist)
Source: The Oncologist - February 3, 2024 Category: Cancer & Oncology Authors: Deniz Can Guven Gozde Kavgaci Enes Erul Masood Pasha Syed Tara Magge Anwaar Saeed Suayib Yalcin Ibrahim Halil Sahin Source Type: research
Comparison of Large Language Models in Answering Immuno-Oncology Questions: A Cross-Sectional Study
CONCLUSION: ChatGPT-4 and ChatGPT-3.5 are potentially powerful tools in immuno-oncology, whereas Google Bard demonstrated relatively poorer performance. However, the risk of inaccuracy or incompleteness in the responses was evident in all 3 LLMs, highlighting the importance of expert-driven verification of the outputs returned by these technologies.PMID:38309720 | DOI:10.1093/oncolo/oyae009 (Source: The Oncologist)
Source: The Oncologist - February 3, 2024 Category: Cancer & Oncology Authors: Giovanni Maria Iannantuono Dara Bracken-Clarke Fatima Karzai Hyoyoung Choo-Wosoba James L Gulley Charalampos S Floudas Source Type: research
